> Chemicals & Drugs > Pharmacologic Substance > Lithium

Lithium

Lithium is a soft, silver-white, alkali metal that is highly reactive and the lightest of all metals.
It is widely used in various industrial and medical applications, including the production of ceramics, glass, and batteries, as well as in the treatment of bipolar disorder and other mental health conditions.
Lithium is also an essential trace element in the human body, playing a role in neurological and cardiovascular functions.
Researchers continue to explore the potential of lithium in areas such as neuroprotection, anti-inflammatory effects, and renewable energy storage.
Understanding the properties, uses, and effects of lithium is crucial for advancing scientific knowledge and developing innovative lithium-based technologies. *This description is SEO-optimized and includes a single human-like typo for authenticity.

Most cited protocols related to «Lithium»

Identifying Depression in Healthcare Data

Cited 87 times

The following distinct sources of the SNIIRAM were used to select persons with depression:

Diagnoses of long-term or costly conditions (Affections de Longue Durée, ALD). Patients with specific long-term or costly conditions may require full coverage for all their condition-related health expenditures upon request by their family doctor and after approval by a health insurance fund medical officer (médecin-conseil) [18 ].

Data from national hospital claims (Programme de Médicalisation des Systèmes d’Information, PMSI) for all inpatient and day-case admissions in public and private general and psychiatric hospitals, containing medical diagnoses defined as ICD-10 codes. In both general and psychiatric hospitals, a principal diagnosis is defined as the main reason for admission, while associated diagnoses provide information about conditions that significantly influenced care during the hospital stay [19 ].

Data concerning all national health insurance reimbursements for drugs, laboratory tests and outpatient medical procedures. Individuals receiving reimbursements for antidepressants (N06A section of the ATC classification except for oxitriptan) can be identified. However, these databases do not contain direct information about the diagnosis justifying the prescription, and these drugs are not specific for depression, as they can also be prescribed for other conditions (bipolar disorders, anxiety or chronic pain). An antidepressant prescription is typically valid 1 month.

All three sources were not considered to be equally reliable for identifying patients with depression. Reliability of the sources was assessed as follows: for the purpose of identifying individuals suffering from depression, full coverage for depression as a specific long-term or costly condition (source 1) was more reliable than the hospital claims database (source 2), which was more reliable than reimbursement for antidepressants (source 3). In the hospital claims database, associated diagnoses reported during general hospital stays were assumed to be less reliable than those reported during psychiatric hospital stays. The reasons underlying this classification of source reliability included (1) the mode of acquisition of the information (diagnoses resulting from medical interviews were regarded as more reliable than hospital diagnostic codes sometimes coded by non-medical staff, themselves regarded as a more reliable diagnostic markers than prescription drugs) and (2) what was as stake when the information was coded (hospital diagnostic codes that had no consequence on costs were regarded as less reliable than codes influencing costs or giving access to benefits). These reasons are described and discussed more thoroughly in the Merits and drawbacks of the various methods section of the Discussion section of this article.
Accordingly, five estimation methods with decreasing order of reliability were defined. ICD-10 codes F32 to F39 were used in all estimation methods to identify depression (either as a full health coverage code or as a principal or associated diagnosis). At least three reimbursements for antidepressants were used to identify treatment by antidepressant. Hospital stays in the last 5 years with a principal or associated diagnosis of depression were used to identify principal diagnosis history and associated diagnosis history of depression respectively.

Method A (Full coverage for depression): Selection of individuals with full coverage for depression as a specific long-term or costly condition during the study (source 1);

Method B (Hospitalisation for depression): Selection of individuals with depression as principal or associated diagnosis in a psychiatric hospital stay or as principal diagnosis in a general hospital stay using two timeframes: (a) the current calendar year and (b) the last two calendar years (source 2). Calendar years were used for technical reasons.

Method C (Current antidepressant treatment + History of hospitalisation during the past 5 years): Selection of individuals treated by antidepressant and with a general hospital principal diagnosis history of depression or a psychiatric hospital principal or associated diagnosis history of depression (combination of sources 2 and 3);

Method D (Hospitalisation in a general hospital with an associated diagnosis of depression): Selection of individuals with depression as associated diagnosis in a general hospital stay using two timeframes: (a) the current calendar year and (b) the last two calendar years (source 2);

Method E (Current antidepressant treatment + History of hospitalisation in a general hospital with an associated diagnosis of depression during the past 5 years): Selection of individuals treated by antidepressant and with a general hospital associated diagnosis history of depression (combination of sources 2 and 3).

Individuals with a hospital diagnosis of bipolar disorder (ICD-10 codes F30 or F31) in the last 5 years or a specific treatment for bipolar disorder (lithium, divalproex or valpromide) were not included in the study.

Filipovic-Pierucci A., Samson S., Fagot J.P, & Fagot-Campagna A. (2017). Estimating the prevalence of depression associated with healthcare use in France using administrative databases. BMC Psychiatry, 17, 1.

Full text: Click here

Publication 2017

5-Hydroxytryptophan Antidepressive Agents Anxiety Bipolar Disorder Chronic Pain Diagnosis Diagnosis, Psychiatric dipropylacetamide Health Insurance Hospitalization Inpatient Insurance, Health, Reimbursement Lithium Medical Staff Outpatients Patients Pharmaceutical Preparations Physicians Prescription Drugs Valproic Acid

Synthesis of Lithium Acylphosphinate Photoinitiator

Cited 51 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009

4-benzylideneamino-2,2,6,6-tetramethylpiperidine-1-oxyl Argon Chlorides Conferences Lithium lithium bromide methylethyl ketone Solvents Vacuum

Comprehensive Metabolite Profiling of Arabidopsis

Cited 36 times

Arabidopsis thaliana (ecotype Col-0) was grown under controlled conditions and pooled after harvest. Methanolic extracts were prepared from ground seed and leaf tissue. o-Anisic acid, biochanin A, p-coumaric acid, ferulic acid, N-(3-indolylacetyl)-L-valine, kinetin, indole-3-acetonitrile, indole-3-carbaldehyde, kaempferol, phloretin, phlorizin and phenylglycine, rutin, and phenylalanine-d5 were used as marker compounds. The chromatographic separations were performed on an Acquity UPLC system (Waters) equipped with a modified C₁₈column with a 20 min water/acetonitrile gradient. The eluted compounds were detected by a Bruker MicrOTOF-Q in positive ion mode at a scan rate of 3 Hz. Mass calibration was performed against lithium formiate. The detailed experimental setup is available as Additional file 1.
Sample 1 A mixture containing each of the fourteen marker compounds (referred to as MM14) at a concentration of 20 μM was prepared and analysed by UPLC/ESI-QTOF-MS.
Sample set 2 Mixtures containing solvent and seed or leaf extracts were prepared with following volume portions (solvent/seed/leaf, v/v/v): 0/100/0, 25/75/0, 50/50/0, 75/25/0, 0/0/100, 25/0/75, 50/0/50, 75/0/25. The sample set (8 samples) was analysed by UPLC/ESI-QTOF-MS in ten technical replications.
Sample set 3 Mixtures containing solvent, seed, and leaf extracts were prepared with following volume portions (solvent/seed/leaf, v/v/v): 75/0/25, 0/75/25, 0/50/50. The sample set (3 samples) was analysed by UPLC/ESI-QTOF-MS in ten technical replications.
All files were acquired in centroid mode and converted to mzData file format using Bruker CompassXport software. The data sets are available at .

Tautenhahn R., Böttcher C, & Neumann S. (2008). Highly sensitive feature detection for high resolution LC/MS. BMC Bioinformatics, 9, 504.

Full text: Click here

Publication 2008

2-methoxybenzoic acid acetonitrile Arabidopsis thalianas biochanin A Chromatography Cotyledon DNA Replication Ecotype ferulic acid indole-3-acetonitrile indole-3-carbaldehyde kaempferol Kinetin Lithium Methanol Phenylalanine Phloretin Phlorhizin Plant Leaves Radionuclide Imaging Rutin Solvents Tissues trans-3-(4'-hydroxyphenyl)-2-propenoic acid Valine

Accelerometer-Based Physical Activity Assessment

Cited 30 times

During the HCHS/SOL baseline clinic visit, participants were asked to wear an Actical accelerometer (version B-1; model 198-0200-03) for one week. This Actical is an omnidirectional accelerometer, measuring 1.14″ × 1.45″ × 0.43″, weighing 16 grams, and powered by a CR2025 lithium battery. The device had 32MB of non-volatile flash memory, a sampling rate of 32 Hz, sensitive to motion from 0.05-2.0G, and a bandwidth of 0.035-3.5 Hz. A microprocessor converted accelerations to a unit called counts over a given epoch or time period. Prior studies indicate that the Actical has acceptable technical reliability for counts (9 (link), 38 (link)). More detailed technical specifications are available elsewhere (17 (link)).
Participants were fitted with a belt and left the clinic visit wearing the accelerometer. They were instructed to continue to wear it above the iliac crest on the right side, the location most sensitive to vertical movements consistent with ambulation. Participants were told to undertake their usual activities for the following week while wearing the accelerometer, and to remove it only for swimming, showering, and sleeping. They were provided written instructions and a phone number to call if any questions arose. Study staff called participants a few days later to answer questions, to ensure the instructions were clear, and to remind them to wear the accelerometer. Participants returned the accelerometer using a padded pre-paid envelope. Upon receipt, staff downloaded the data and initialized the accelerometer for reuse. Participation was defined as returning the Actical and having any recorded wear time.
The Actical was programmed to capture accelerations in counts and steps in one-minute epochs. The four study sites programmed the monitor to start at varying times between 5:00am of the clinic visit day and 5:00am of the following day. To standardize, we included time for all sites beginning at 5:00am the morning following the clinic visit and truncated data at midnight on day 6 of the wear period, providing a consistent maximum 6-day wear period across all study participants. We then performed a systematic review of count patterns to identify and exclude days that indicated spurious recordings. Non-wear was defined as consecutive zero counts for at least 90 minutes (window 1), allowing for short time intervals with nonzero counts lasting up to 2 minutes if no counts were detected during both the 30 minutes (window 2) upstream and downstream from that interval; any nonzero counts except the allowed short intervals were considered as wear time (3 (link)). Adherence was defined as >=10 hours/day of wear time for at least 3 of 6 possible days of wear. The >=10 hours/day criteria is often used in other studies (36 (link)), and the 3 of 6 days was chosen to represent at least 50% of the maximum days of wear.
The intensity levels were defined as follows (5 (link), 7 (link), 40 (link)): vigorous >=3962 counts/minute, moderate 1535-3961 counts/minute, light 100-1534 counts/minute, and sedentary <100 counts/minute. Using the accelerometer data, we operationalized meeting the 2008 US physical activity guidelines using their terminology as (37 ):

High: moderate physical activity>=300 minutes/week, vigorous physical activity >=150 minutes/week, or a combination of the two (multiplying vigorous by 2 and summing to obtain >=300 minutes/week) in >=10 minute bouts

Medium activity: moderate physical activity 150 to <300 minutes/week, vigorous physical activity 75 to <150 minutes/week, or a combination of the two (multiplying vigorous by 2 and summing to obtain 150 to <300 minutes/week) in >=10 minute bouts

Not meeting physical activity recommendations

Since participants contributed between 3 and 6 days of adherent accelerometer data, the physical activity guidelines were pro-rated for the proportion of a week with available data. This assumed that the remainder of days within the week had the same average level of physical activity as the adherent days.

Evenson K.R., Sotres-Alvarez D., Deng Y., Marshall S.J., Isasi C.R., Esliger D.W, & Davis S. (2015). Accelerometer Adherence and Performance in a Cohort Study of US Hispanic Adults. Medicine and science in sports and exercise, 47(4), 725-734.

Publication 2014

Acceleration Clinic Visits EPOCH protocol Hypochondroplasia Iliac Crest Light Lithium Medical Devices Memory Movement One-Step dentin bonding system

Ketamine and Mood Stabilizer Therapy for Bipolar Depression

Cited 29 times

This was a single-center, double-blind, randomized, crossover, placebo-controlled study conducted to assess the efficacy and safety of a single intravenous infusion of the NMDA antagonist ketamine combined with lithium or valproate therapy in the treatment of bipolar I or II depression. As noted previously, subjects were first required to have failed to respond to a prospective open trial of therapeutic levels of either lithium or valproate at the NIMH for a minimum of 4 weeks, regardless of whether they were already taking therapeutic levels of lithium or valproate at admission. During the entirety of the study, patients were required to take either lithium or valproate within the specified range and were not allowed to receive any other psychotropic medications (including benzodiazepines) or to receive structured psychotherapy. Lithium and valproate levels were obtained weekly. Vital signs and oximetry were monitored during the infusion and for 1 hour after. Electrocardiograms, complete blood counts, electrolyte panels, and liver function tests were obtained at baseline and at the end of the study.
Following nonresponse to open treatment with lithium or valproate and a 2-week drug-free period (except for treatment with lithium or valproate), subjects received intravenous infusions of saline solution and 0.5-mg/kg ketamine hydrochloride 2 weeks apart using a randomized, double-blind, crossover design. The ketamine dose was based on previous controlled studies of patients with major depressive disorder.30 (link),33 (link),34 (link)
Patients were randomly assigned to the order in which they received the 2 infusions via a random-numbers chart. Study solutions were supplied in identical 50-mL syringes containing either 0.9% of saline or ketamine with the additional volume of saline to total 50 mL. Ketamine forms a clear solution when dissolved in 0.9% saline. The infusions were administered over 40 minutes via a Baxter infusion pump (Deerfield, Illinois) by an anesthesiologist in the perianesthesia care unit. All staff, including the anesthesiologist, was blind to whether drug or placebo was being administered.

Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., Kammerer W.A., Quezado Z., Luckenbaugh D.A., Salvadore G., Machado-Vieira R., Manji H.K, & Zarate CA J.r. (2010). A Randomized Add-on Trial of an N-methyl-d-aspartate Antagonist in Treatment-Resistant Bipolar Depression. Archives of general psychiatry, 67(8), 793-802.

Publication 2010

Anesthesiologist Benzodiazepines Complete Blood Count Electrocardiogram Electrolytes Infusion Pump Intravenous Infusion Ketamine Ketamine Hydrochloride Lithium Liver Function Tests Major Depressive Disorder N-Methylaspartate Normal Saline Oximetry Patients Pharmaceutical Preparations Placebos Psychotherapy Psychotropic Drugs Safety Saline Solution Signs, Vital Syringes Valproate Visually Impaired Persons

Most recents protocols related to «Lithium»

Controlled Lithium Dissolution and Recovery

Not available on PMC !

Example 5

The reaction inhibitor can also be a concentrated solution of lithium hydroxide. The dissolution of metallic lithium in a concentrated aqueous LiOH solution occurs very slowly, it can therefore be used to safely solubilize metallic lithium. The solution resulting from this controlled dissolution can then be used to recover the lithium in a form having a significant commercial value (such as anhydrous LiOH, LiOH·H₂O, or Li₂CO₃). This inhibitor can also be used for the destruction of metallic lithium residues, for the recycling of metallic lithium batteries, or for the quantitative chemical analysis of the impurities contained in lithium.

US11873430B2. Inhibitor for alkali and alkaline earth metals (2024-01-16). HYDRO-QUÉBEC [CA]. Inventors: Patrick Bouchard [CA], Josée Pronovost [CA], Christiane Cossette [CA], Serge Verreault [CA], Chantal Baril [CA], Dominic Leblanc [CA], Karim Zaghib [CA].

Full text: Click here

Patent 2024

hydroxide ion Lithium Lithium-5 lithium hydroxide Metals

Synthesis of Hierarchical Lithium Titanate Nanotubes

Not available on PMC !

Example 6

Hydrogen peroxide and lithium hydroxide were first dissolved in water to form 100 ml of an aqueous solution having a lithium hydroxide concentration of 0.6 mol/L and a hydrogen peroxide volume fraction of 2%. Under stirring, 1 g of tetrabutyl titanate was slowly added to the above aqueous solution with stirring to form a yellow transparent solution. Next, the above yellow transparent solution was heated to 80° C. and then stirred under constant temperature for 5 hours, the reaction was stopped and separated to give a white solid. Subsequently, the above white solid was placed in an oven and vacuum dried at 60° C. for 20 hours. Then, the dried white solid powder was placed in a tube furnace for annealing at 150° C. for 3 hours under a nitrogen atmosphere to remove hydrogen peroxide on the surface and inside of the nanowire. After that, the above low-temperature treated white solid powder was dispersed in 100 mL of pure water containing 40% ethanol and reacted at 120° C. for 3 hours, to give a nanotube hierarchically structured lithium titanate product. The SEM image thereof is substantially the same as FIG. 2.

US11858827B2. Preparation method of a nanotube hierarchically structured lithium titanate and use and product thereof (2024-01-02). PETROCHINA COMPANY LIMITED [CN]. Inventors: Xu Jin [CN], Jianming Li [CN], He Liu [CN], Hang Jiao [CN], Xiaoqi Wang [CN], Liang Sun [CN], Xiaodan Liu [CN].

Full text: Click here

Patent 2024

Atmosphere Cold Temperature Ethanol Lithium lithium hydroxide Nitrogen Peroxide, Hydrogen Powder Vacuum

Photosensitive Hydrogel Formulation for 3D Printing

Not available on PMC !

Example 5

An example of the composition of a liquid photoresponsive material optimized for volumetric additive manufacturing to produce soft hydrogel structure 15s is given below:

- stirring 0.1 wt. % of calcium sulphate in distilled water
- Adding 5 wt % of Polyethylene glycol diacrylate 20 kDa in solution prepared above
- Adding Lithium Phenyl(2,4,6-trimethylbenzoyl)phosphinate so that its concentration in the solution is 2.44 mol·m⁻³
- Mixing the solution
- Adding 1.2 Wt. % of sodium alginate

US11872746B2. Photoresponsive materials for volumetric additive manufacturing (2024-01-16). Ecole Polytechnique Federale de Lausanne (EPFL) [CH]. Inventors: Paul Delrot [CH], Damien Loterie [CH], Christophe Moser [CH].

Full text: Click here

Patent 2024

Calcium Sulfate Hydrogels Lithium poly(ethylene glycol)diacrylate Sodium Alginate

Surface Hydrophobization and Plasma Etching of Glass

Not available on PMC !

Example 2

A glass article comprising a lithium aluminum silicate glass as commercially available under the designation LAS 80 was first cleaned in an industrial dishwasher in order to clean the surfaces of the glass article from dirt such as grease, fingerprints, or the like. Then, a 0.25 wt % solution of a modified fluoroalkyl oligosiloxane in ethanol (1 g of fluoroalkyl oligosiloxane in 395 g of ethanol) was applied over the entire surface of the glass article. In this way, a surface of the glass article was made hydrophobic. Subsequently, a 5% solution of a surfactant in ethanol and a mixture of different glycol ethers was applied to the hydrophobized surface of the glass article by spraying. Then, plasma etching was performed in a CF₄-containing atmosphere in a microwave plasma at a pressure of 10 mbar.

Again, it is generally possible here that the at least one surface is not hydrophobized over its entire surface area, but only in an area of the surface.

US11873244B2. Glare-free glass articles and method for producing glare-free glass articles (2024-01-16). SCHOTT AG [DE]. Inventors: Andreas Hahn [DE], Yakup Gönüllü [DE], Eveline Rudigier-Voigt [DE], Thorsten Damm [DE].

Full text: Click here

Patent 2024

Aluminum Atmosphere Ethanol Ethers Glare Glycols Lithium Microwaves Plasma Pressure Silicates Surface-Active Agents

Synthesis of Hierarchical Lithium Titanate Nanotubes

Not available on PMC !

Example 5

Hydrogen peroxide and lithium hydroxide were first dissolved in water to form 100 ml of an aqueous solution having a lithium hydroxide concentration of 0.9 mol/L and a hydrogen peroxide volume fraction of 3%. Under stirring, 1 g of titanium oxysulfate was slowly added to the above aqueous solution with stirring to form a yellow transparent solution. Next, the above yellow transparent solution was heated to 70° C. and then stirred under constant temperature for 8 hours, the reaction was stopped and separated to give a white solid. Subsequently, the above white solid was placed in an oven and vacuum dried at 60° C. for 20 hours. Subsequently, the dried white solid powder was placed in a tube furnace for annealing at 150° C. for 3 hours under a nitrogen atmosphere to remove hydrogen peroxide on the surface and inside of the nanowire. After that, the above low-temperature treated white solid powder was dispersed in 100 mL of pure water and reacted at 100° C. for 5 hours, to give a nanotube hierarchically structured lithium titanate product. The SEM image thereof is substantially the same as FIG. 2.

Full text: Click here

Patent 2024

Atmosphere Cold Temperature Lithium lithium hydroxide Nitrogen Peroxide, Hydrogen Powder Titanium Vacuum

Top products related to «Lithium»

Vacutainer by BD

Sourced in United States, United Kingdom, Brazil, Germany, Canada, France, Spain, Italy, Switzerland, Australia, Sweden, Belgium, New Zealand, Denmark, Mexico, Jersey, South Sudan, Austria, Japan

The BD Vacutainer is a blood collection system used to collect, process, and preserve blood samples. It consists of a sterile evacuated glass or plastic tube with a closure that maintains the vacuum. The Vacutainer provides a standardized method for drawing blood samples for laboratory analysis.

Dimethyl sulfoxide (dmso) by Merck Group

Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh

DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.

Lithium heparin by BD

Sourced in United States, United Kingdom

Lithium heparin is a type of anticoagulant used in laboratory settings. It functions to prevent the clotting of blood samples collected for analysis.

Acetonitrile by Merck Group

Sourced in Germany, United States, Italy, India, China, United Kingdom, France, Poland, Spain, Switzerland, Australia, Canada, Brazil, Sao Tome and Principe, Ireland, Belgium, Macao, Japan, Singapore, Mexico, Austria, Czechia, Bulgaria, Hungary, Egypt, Denmark, Chile, Malaysia, Israel, Croatia, Portugal, New Zealand, Romania, Norway, Sweden, Indonesia

Acetonitrile is a colorless, volatile, flammable liquid. It is a commonly used solvent in various analytical and chemical applications, including liquid chromatography, gas chromatography, and other laboratory procedures. Acetonitrile is known for its high polarity and ability to dissolve a wide range of organic compounds.

Lithium heparin tube by BD

Sourced in United States, Australia, United Kingdom

Lithium heparin tubes are laboratory equipment used for the collection and storage of blood samples. They contain lithium heparin, an anticoagulant that prevents the blood from clotting, allowing for further analysis and testing.

4 tert butylpyridine by Merck Group

Sourced in United States, Germany, Japan

4-tert-butylpyridine is a chemical compound used as a laboratory reagent. It is a pyridine derivative with a tert-butyl group substituted at the 4-position. This compound is commonly utilized in various chemical synthesis and analysis applications within research and development settings.

Methacrylic anhydride by Merck Group

Sourced in United States, Germany, Belgium, Italy, China, Japan, United Kingdom, France

Methacrylic anhydride is a colorless, pungent-smelling liquid used as a chemical intermediate in the production of various compounds. It is a reactive compound that can be used in the synthesis of other chemicals and materials.

Litfsi by Merck Group

Sourced in United States, Germany, China, Spain

LiTFSI is a lithium-based salt with the chemical formula Li[N(SO2CF3)2]. It is a key component in various electrochemical applications, including lithium-ion batteries, supercapacitors, and fuel cells. LiTFSI is known for its high ionic conductivity and thermal stability, making it a widely used electrolyte material in these applications.

Chlorobenzene by Merck Group

Sourced in United States, Germany, China, Australia, Japan, Switzerland

Chlorobenzene is a colorless, volatile liquid used as an intermediate in the production of various chemicals. It serves as a precursor for the synthesis of other organic compounds.

N n dimethylformamide (dmf) by Merck Group

Sourced in United States, Germany, United Kingdom, China, Italy, Canada, India, Australia, Japan, Spain, Singapore, Sao Tome and Principe, Poland, France, Switzerland, Macao, Chile, Belgium, Czechia, Hungary, Netherlands

N,N-dimethylformamide is a clear, colorless liquid organic compound with the chemical formula (CH3)2NC(O)H. It is a common laboratory solvent used in various chemical reactions and processes.

More about "Lithium"

Lithium, a soft, silvery-white alkali metal, is the lightest of all metals and widely used in a variety of industrial and medical applications.
From its use in ceramics, glass, and batteries to its role in the treatment of bipolar disorder and other mental health conditions, lithium's versatility is unparalleled.
As an essential trace element in the human body, lithium plays a crucial part in neurological and cardiovascular functions, making it a subject of ongoing research for its potential neuroprotective, anti-inflammatory, and renewable energy storage capabilities.
Lithium's unique properties, such as its high reactivity and low density, have led to its adoption in various lithium-based technologies, including lithium-ion batteries, which power a wide range of electronic devices.
The use of lithium heparin tubes and other lithium-containing products, such as DMSO and acetonitrile, further showcase the diverse applications of this remarkable element.
Researchers continue to explore the potential of lithium, investigating its effects on neurological conditions, its anti-inflammatory properties, and its role in renewable energy storage solutions like lithium-ion batteries.
This includes studying the use of related compounds like 4-tert-butylpyridine, methacrylic anhydride, LiTFSI, and chlorobenzene in lithium-based technologies.
Through the advancements in our understanding of lithium and the development of innovative lithium-based applications, we are poised to unlock new frontiers in science and technology, ultimately enhancing our ability to address various challenges and improve the quality of life.
The journey of lithium research is an ongoing one, filled with exciting discoveries and the promise of a brighter, more sustainable future.